Skip to content

09939.HK

Kintor Pharmaceutical Limited

HKSE · Healthcare · Biotechnology · CN

HKD 1.82
−3.96%
Ask drillr

Year over year

Reported trailing growth

Revenue
EBITDA
EBIT
+66.0%
EPS
+79.2%
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
+553.6%
EBITDA
-9.6%
EBIT
-38.2%
Net income
-28.9%
EPS
-22.2%
Free cash flow
+17.3%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026